RETROSPECTIVE ANALYSIS OF TREATMENT WITH BEVACIZUMAB IN PATIENTS WITH ADVANCED AND RECURRENT NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER IN OUR INSTITUTE

    loading  Checking for direct PDF access through Ovid

Abstract

Background

The addition of bevacizumab to platinum-based regimens improved the response rate and the progression-free survival (PFS) with advanced non-squamous NSCLCs. We retrospectively evaluated the efficacy and safety of treatment with bevacizumab in patients with advanced and recurrent non-squamous NSCLC in our institute.

Methods and result

Twenty-eight advanced and recurrent non-squamous NSCLC patients received bevacizumab between December 2009 and January 2012 in our institute. The median age was 66 years (range: 47–82); male/female, 20 (71%)/8 (29%); ECOG PS 0/1, 18 (64%)/10 (36%); stage IIIA/IIIB/IV, 1 (4%)/3 (11%)/24 (86%); adeno/NSCLC, 26 (93%)/2 (7%); EGFR mutat/wild/unknown, 4/15/9; treatment line first/second/third/fourth, 13/9/4/2 and combination chemotherapy CBDCA + PTX/CBDCA + PEM/PEM, 7/19/2; CR/PR/SD/PD/NE, 1/13/10/1/3; and response rate (RR) was 56% and disease control rate (DCR) was 96%. As after second-line treatment, RR was 46.2% and DCR was 100%. Grade 3/4 hematological adverse events were leukocytopenia (39%), neutropenia (46%), and thrombocytopenia (17.9%). Grade 3/4 non-hematological toxicities were appetite loss (3.5%), peripheral sensory neuropathy (3.5%) and pneumonia (3.4%). Grade 1/2 hypertension (21.4%) and epistaxis (14.3%) as the characteristic advance events of bevacizumab were observed.

Conclusion

Bevacizumab in combination with cytotoxic drugs was effective in disease control and well-tolerated regimen for the treatment of patients with advanced and recurrent non-squamous NSCLC.

Related Topics

    loading  Loading Related Articles